Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment

Apnimed announced positive data across multiple endpoints from a Phase 2 randomized, double-blind, placebo-controlled, four-period, single-dose crossover factorial clinical trial (APC-003), and a 28-day open-label extension study, evaluating AD109 as a treatment in patients with mild to severe OSA.

Apnimed Expands Executive Leadership Team Appointing Rob Rode Chief Commercial Officer

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that Rob Rode has joined the company as Chief Commercial Officer. Mr. Rode has more than 27 years of experience leading global sales and marketing efforts in the biopharmaceutical field and will be responsible for developing and executing Apnimed’s commercial strategy.

Apnimed to Present at the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass. May 25, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Jefferies Virtual Healthcare Conference, held June 1-4, 2021. Apnimed’s presentation is scheduled for Tuesday, June 1st at 4:30pm ET. Management will be available June 1st throughout the day for virtual one-on-one meetings.

New Data Presented at American Thoracic Society Meeting Reinforces the Potential of an Oral Drug Combination Therapy for the Treatment of Obstructive Sleep Apnea

CAMBRIDGE, Mass. May 17, 2021 – Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for sleep apnea and related disorders, announced today that researchers from Istituto Auxologico Italiano and Brigham and Women’s Hospital presented data on the company’s investigational treatment for obstructive sleep apnea, AD128, at the American Thoracic Society (ATS) Meeting, taking place from May 14-19, 2021.


By submitting this form, you are consenting to receive marketing emails from: Apnimed, 20 Holyoke Street, Cambridge, MA, 02138, You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact